Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
We report the case of an unresected, metastatic gastric cancer, which was treated with a very short course of the oral 5-fluorouracil (5-FU) prodrug S-1. The patient had to discontinue chemotherapy during the first treatment cycle due to severe toxicity, but achieved a pathologically confirmed, long-term complete response of her primary tumour, a diffuse-type poorly differentiated adenocarcinoma.
Schöffski
P
P
Abt. Hämatologie/Onkologie, Medizinische Hochschule Hannover, Germany. Schoeffski.Patrick@MH-Hannover.de
Chollet
P
P
Ganser
A
A
Wiese
K H
KH
Rambusch
E
E
de Vries
M J
MJ
Hanauske
A
A
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology*; D006801:Humans; D010094:Oxonic Acid / Q000494:pharmacology*; D011355:Prodrugs / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000494:pharmacology*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011355:Prodrugs; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D005472:Fluorouracil